This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Zangari M, Anaissie E, Barlogie B, Badros A, Desikan R, Gopal AV et al. Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy. Blood 2001; 98: 1614–1615.
Cavenagh JD, Oakervee H . Thalidomide in multiple myeloma: current status and future prospects. Br J Haematol 2003; 120: 18–26.
Barlogie B, Jagannath S, Desikan KR, Mattox S, Vesole D, Siegel D et al. Total therapy with tandem transplants for newly diagnosed multiple myeloma. Blood 1999; 93: 55–65.
Osman K, Comenzo R, Rajkumar SV . Deep venous thrombosis and thalidomide therapy for multiple myeloma. N Engl J Med 2001; 344: 1951–1952.
Zervas K, Dimopoulos MA, Hatzicharissi E, Anagnostopoulos A, Papaioannou M, Mitsouli Ch, et al., Greek Myeloma Study Group. Primary treatment of multiple myeloma with thalidomide, vincristine, liposomal doxorubicin and dexamethasone (T-VAD doxil): a phase II multicenter study. Ann Oncol 2004; 15: 134–138.
Minnema MC, Fijnheer R, De Groot PG, Lokhorst HM . Extremely high levels of von Willebrand factor antigen and of procoagulant factor VIII found in multiple myeloma patients are associated with activity status but not with thalidomide treatment. J Thromb Haemost 2003; 1: 445–449.
Cavo M, Zamagni E, Cellini C, Tosi P, Cangini D, Cini M et al. Deep-vein thrombosis in patients with multiple myeloma receiving first-line thalidomide-dexamethasone therapy. Blood 2002; 100: 2272–2273.
Author information
Authors and Affiliations
Corresponding author
Additional information
Presented partly as abstract at the 9th International Workshop 2003, Salamanca, Spain
Rights and permissions
About this article
Cite this article
Minnema, M., Breitkreutz, I., Auwerda, J. et al. Prevention of venous thromboembolism with low molecular-weight heparin in patients with multiple myeloma treated with thalidomide and chemotherapy. Leukemia 18, 2044–2046 (2004). https://doi.org/10.1038/sj.leu.2403533
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.leu.2403533
This article is cited by
-
Coarse-grained molecular dynamics simulations of fibrin polymerization: effects of thrombin concentration on fibrin clot structure
Journal of Molecular Modeling (2018)
-
Fibrin polymerization simulation using a reactive dissipative particle dynamics method
Biomechanics and Modeling in Mechanobiology (2018)
-
Thalidomide treatment for patients with previously untreated multiple myeloma: a meta-analysis of randomized controlled trials
Tumor Biology (2016)
-
Initial cytoreductive treatment with thalidomide plus bolus vincristine/doxorubicin and reduced dexamethasone followed by autologous stem cell transplantation for multiple myeloma
Investigational New Drugs (2011)
-
Effect of thalidomide with melphalan and prednisone on health-related quality of life (HRQoL) in elderly patients with newly diagnosed multiple myeloma: a prospective analysis in a randomized trial
Annals of Hematology (2011)